Search Patents
  • CDNAS encoding mouse and rat type-2 angiotensin II receptors and their expression in host cells
    Patent number: 5556780
    Abstract: An angiotensin II type 2 receptor (AT.sub.2 receptor), structurally related cell receptors, nucleic acids encoding such AT.sub.2 receptors, AT.sub.2 receptor-related peptides, and methods of using AT.sub.2 receptors and AT.sub.2 receptor-encoding nucleic acids are provide. AT.sub.2 receptor-specific binding compounds are disclosed including antibodies to AT.sub.2 receptor epitopes. The invention provides AT.sub.2 receptor-based pharmaceutical compositions and AT.sub.2 receptor-based methods rot screening chemical libraries for regulators of cell growth/differentiation. In particular, the invention provides methods for identifying agonists and antagonists of the disclosed AT.sub.2 receptor. Such compositions find broad utility in the treatment of cardiovascular disease, cancer, reproductive disease, etc.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: September 17, 1996
    Assignee: The Board of Trustees for the Leland Stanford Junior University
    Inventors: Victor Dzau, Masahi Mukoyama
  • Methods for implanting cells
    Patent number: 6579313
    Abstract: A method for implanting cells onto a prosthesis includes the steps of: (a) providing a prosthesis including a porous tube, where at least 25% of the pores on the inner surface of the tube have diameters of more than about 40 &mgr;m, at least 25% of the pores on the outer surface of the tube have diameters of less than about 30 &mgr;m, and the tube includes a substantially continuous layer of a biocompatible material; (b) contacting the prosthesis with a suspension of cells; and (c) providing a pressure differential between the inner surface and the outer surface, whereby the cells are retained in the pores of the inner surface. A method for obtaining an endothelial cell culture from a blood sample involved:(a) obtaining a sample for mononuclear cells from a blood sample; and (b) culturing the sample of mononuclear cells, without further cell separation, on a cell adhesive polymer-coated solid support in the presence of endothelial growth factors.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: June 17, 2003
    Assignee: The Bringham and Women's Hospital
    Inventors: Victor J. Dzau, Richard E. Pratt, Michael J. Mann, Afshin Ehsan, Daniel P. Griese
  • Intracellular delivery of nucleic acids using pressure
    Patent number: 5922687
    Abstract: Naked nucleic acids (DNA, RNA, and/or analogs), drugs, and/or other molecules in an extracellular environment enter cells in living intact tissue upon application of pressure to the cells and extracellular environment. Nucleic acids localize to the cell nuclei. Transfection efficiencies greater than 90% are achievable for naked DNA and RNA. A sealed enclosure, defined by an enclosing means and/or tissue, contains the cells and their extracellular environment. The enclosure is pressurized to an incubation pressure on the order of atmospheres. A protective inelastic sheath may be used to prevent distension and trauma in tissue that is part of the enclosure boundary. Suitable enclosures include pressurization chambers and organs such as blood vessels or the heart. Parts of organs, entire organs, and/or entire organisms are pressurized. Suitable target tissue types include blood vessel (in particular vein) tissue, heart, kidney, liver, and bone marrow tissue.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: July 13, 1999
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael J. Mann, Frank P. Diet, Victor J. Dzau, Gary H. Gibbons, Heiko Von Der Leyen
  • Apparatus and method for delivering a nucleotide into cell nuclei
    Patent number: 5766901
    Abstract: The invention presents a system for inducing cells in living intact tissue, in vivo or ex vivo, to accept nucleotides from their extracellular environment and to localize those nucleotides into the cells' nuclei. This system relies on the fact that, when subjected to high pressure, cells take in nucleotides and localize those nucleotides into their nuclei with a transfection rate of greater than 90% in some cases. This invention employs various techniques for placing under high pressure either cells in isolated tissue cultures, or cells in tissues still connected to a living body.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: June 16, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael J. Mann, Frank P. Diet, Victor J. Dzau, Gary H. Gibbons, Heiko Von der Leyen
  • Inhibition of proliferation of vascular smooth muscle cell
    Patent number: 5821234
    Abstract: This invention encompasses a method for inhibiting vascular cellular activity of cells associated with vascular lesion formation in mammals which involves administering an effective dosage of at least one antisense sequence to at least one gene expressing a cyclin or a cyclin dependent kinase which inhibits the expression of the gene. More particularly, the invention involves administering antisense sequences which inhibit the expression of cyclin A, B1, B2, C, D1, D2, D3, E or cyclin X (p46) cyclin X and cyclin dependent kinase cdc2, cdk2, cdk4 or cdk5. It is preferable to use two antisense sequences each from a different cyclin or cyclin dependent kinase. The cyclin or cyclin kinase depending kinase dosage is preferable administered in combination with proliferating cell nuclear antigen (PCNA). Antisense methods and compositions direct to inhibiting the expression of growth factors such as TGF-.beta..sub.1, TGF, bFGF, PDGF are also contemplated by the present invention.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: October 13, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Victor J. Dzau
  • Inhibition of proliferation of vascular smooth muscle cell
    Patent number: 5869462
    Abstract: This invention encompasses a method for inhibiting vascular cellular activity of cells associated with vascular lesion formation in mammals which involves administering an effective dosage of at least one antisense sequence to at least one gene expressing a cyclin or a cyclin dependent kinase which inhibits the expression of the gene. More particularly, the invention involves administering antisense sequences which inhibit the expression of cyclin A, B1, B2, C, D1, D2, D3, E or cyclin X (p46) cyclin X and cyclin dependent kinase cdc2, cdk2, cdk4 or cdk5. It is preferable to use two antisense sequences each from a different cyclin or cyclin dependent kinase. The cyclin or cyclin kinase depending kinase dosage is preferable administered in combination with proliferating cell nuclear antigen (PCNA). Antisense methods and compositions direct to inhibiting the expression of growth factors such as TGF-.beta..sub.1, TGF, bFGF, PDGF are also contemplated by the present invention.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: February 9, 1999
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Victor J. Dzau
Narrow Results

Filter by US Classification